PC08.01 Debate #1: Locally Ablative Therapies Should Be Standard Treatment for Patients With NSCLC Oligometastese (PRO)

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.114
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

PC08.02 Debate #1: Locally Ablative Therapies Should Be Standard Treatment for Patients With NSCLC Oligometastese (CON)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Commentary: Sleeve Lobectomy for Centrally Located NSCLC: Should the Approach Be a Matter of Debate?

Journal of Thoracic and Cardiovascular Surgery
Respiratory MedicinePulmonaryCardiovascular MedicineSurgeryCardiology
2019English

Pro: Should Asymptomatic Patients With Moderate-To-Severe OSA Be Treated?

Breathe
PulmonaryRespiratory Medicine
2019English

PC08.07 Debate #3: Brain Metastases With a Driver Mutation Should Be Treated With Systemic Therapy First (PRO)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

PC09.05 Debate 2: Large Cell Neuroendocrine Carcinoma Should Be Treated Like NSCLC or SCLC? - SCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

PRO: Patients With Metastatic/Recurrent Cervical Cancer Should Be Treated With Cisplatin Plus Paclitaxel

Clinical Ovarian Cancer
2011English

Pro/Con Debate: Should Antimicrobial Stewardship Programs Be Adopted Universally in the Intensive Care Unit?

Critical Care
Critical CareIntensive Care Medicine
2010English

Pirfenidone Should Be Prescribed for Patients With Idiopathic Pulmonary Fibrosis: Table 1

Thorax
PulmonaryRespiratory Medicine
2013English

Pro: The Abstinence Period Should Be the Same for All Patients Undergoing Evaluation for Transplant

Clinical Liver Disease
Hepatology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy